SV investment has resulted in the approval of 24 novel therapeutics
SV News
12 April 2022Portfolio NewsSV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months
10 April 2022SV NewsLife Sciences Summit: venture capital plugs gap in funding- 5 April 2022Portfolio NewsCatamaran Bio Appoints Frank Lee as Chair of its Board of Directors
31 March 2022SV NewsKate Bingham interviewed by Beth Rigby, Sky News, on the lessons learnt from the UK Vaccine Taskforce
30 March 2022SV NewsKate Bingham shared the key lessons learnt from the success of the UK Vaccine Taskforce at The Royal Society’s recent Science of COVID-19 event.
24 March 2022Portfolio NewsImbria Pharmaceuticals Appoints John Young to its Board of Directors
19 March 2022Portfolio NewsLoQus23: going upstream to slow Huntington’s disease
8 March 2022Portfolio NewsTRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases- 8 March 2022Portfolio NewsPionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
2 March 2022Portfolio NewsCaraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD
2 March 2022Portfolio NewsRondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
22 February 2022Portfolio NewsEyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies
